Technology Research and Development


In the past decade, these hospitals and individuals have achieved many innovations that enabled the growth of the transplant industry and made it possible to achieve its present-day scale. These achievements include prolonged organ preservation, lower rejection rates, and shortened operation times.

Immunosuppressants

As transplant patients rely on post-transplant immunosuppressants to avoid organ rejection, the rapid development of China’s immunosuppressant technology has greatly contributed to the unprecedented growth of China’s organ transplant industry.

The Chinese government incorporated organ transplantation into its national strategy and listed the research and development of immunosuppressants as national key scientific research projects. For example, the High Technology Research and Development Program (863 Program), National Program on Key Basic Research Projects (973 Program), “985 Project” of the State Key Universities, and China National Natural Science Fund all invested heavily in promoting immunosuppressant research and development. Many domestic transplant related institutions engaged in R&D early on.

Such ample government funding produced fruitful results:

  • Ciclosporin, the first domestic immunosuppressant was, was made by the North China Pharmaceutical Group1
  • “A novel immunosuppressant Fingolimod: research advances”2 and “Research advances in the application of immunosuppressant in organ transplantation” published by the Institute of Basic Medical Sciences, Academy of Military Medical Sciences3
  • A project on research and development of organ transplant immunosuppressant series products conducted by the Lunan Pharmaceutical Group
  • Research in immunosuppressant withdrawal after liver transplantation by the Guangdong Provincial Organ Transplant Center, Sun Yat-sen University Institute of Organ Transplantation4
  • Studies in basic immunology for organ transplantation conducted by the Fudan University Organ Transplant Center5

By 2004, domestic drug development began to catch up, taking almost half of the market share from imported and joint-stock drugs. This greatly lowered the cost of immunosuppressant medications and lifted an economic barrier for many patients who otherwise could not afford to receive organ transplants. It thereby contributed to a rapid growth in transplant volume in China before 2004.6

In 2004, Professor Zhang Yuhai, director of the Urology Department of the Beijing Friendship Hospital, said that over half of kidney transplant patients chose to use domestic immunosuppressants, including not only self-funded patients but also many with free medical service or insurance.7

In 2006, Health Times (owned by People’s Daily) interviewed Yan Lvnan, the director of the liver transplantation center at West China Hospital of Sichuan University. Dr. Yan said that West China Hospital was able to keep the cost of post-transplant maintenance at 30,000 yuan in the first year and an average of 10,000 yuan per year thereafter by using immunosuppressants reasonably, which greatly reduced the cost.8

In March 2006, just before the exposure of forced organ harvesting, the Southern Medicine Economic Institute under the China Food and Drug Administration published a report in its own publication, Medicine Economic Reporter, which said the domestic immunosuppressant market at the time was nearly 10 billion yuan with more than 100 manufacturers of nearly 30 drugs.9

If each patient pays an average of 30,000 RMB per year for immunosuppressants, a10 billion RMB market in 2006 would have supported approximately 333,000 post-transplant patients. Since organ transplantation grew significantly only after 2000, the size of the immunosuppressant drug market in 2006 implies an average of 50,000 to 60,000 transplants were performed each year since 2000.

An immunosuppressant manufacturing plant

According to the 2011 “China Science and Technology Development Report,” China has established a series of new demonstration bases for piloting the production of raw materials and preparations of immunosuppressants. China has also improved its research capacity and development and manufacturing of domestic immunosuppressants, achieved the localization of new immunosuppressive products, reduced medical costs for transplant patients, realized earnings from exports, and strengthened the international competitiveness of the Chinese organ transplant immunosuppressant industry.10

As the patents of several major imported drugs expired, China began to produce a large volume of imitation products in addition to domestically developed drugs. These producers have achieved the same efficacy as imported immunosuppressants but at much lower prices. This increased the market share of domestic drugs. Major producers include Huadong Medicine Co., Ltd, North China Pharmaceutical Group Corporation, and Zhejiang Hisun Pharmaceutical Co., Ltd.11

As transplant hospitals and pharmaceutical companies have widely deflated public transplant data for tax evasion and inability to explain organ sources, it is difficult to determine accurate statistics for domestic immunosuppressant usage. Nevertheless, our research finds that along with the momentous development of China’s organ transplant industry, the immunosuppressant market grew by an average of 13% every year between 2008 and 2014.12

International drug sales data, such as those from IMS Health indicating a 2.3 billion RMB market in 2009,13 reflect only part of the actual size of the Chinese immunosuppressant market. China’s actual immunosuppressant market should be far more than the 10 billion figure in 2006 with its scale reflected by current IMS Health data.

Improved Organ Matching

Professor Tan Jianmin at Fuzhou General Hospital of Nanjing Military Command pioneered HLA and amino acid residue matching technology in China, enabling donors and recipients to be genetically matched before transplantation and significantly improving transplant outcome quality. He was the second-place recipient of the 2001 National Science and Technology Advancement Award.14

Tan also established an anti-HLA antibody screening method that significantly reduced acute rejection events. This technique has since been applied all over the country with Fuzhou General Hospital establishing collaborative relationships with more than 100 hospitals in 19 provinces and cities and organ sharing relationships with 15 transplant centers.15

Prolonged Organ Preservation

Among the hundreds of transplant-related patents in China, about half are related to anti-rejection drugs and organ preservation solutions.

Shanghai Changzheng Hospital of the Second Military Medical University was one of the first in China to perform kidney transplants. Zhu and his team completed research on kidney and multi-organ preservation solutions. After 20 years of clinical application, this product is propelling China to the forefront of this field internationally.16 An archived webpage of Changzheng Hospital stated, “95% of hospitals in China use the organ preservation solution we developed.”17

Shortened Operation and Hospitalization Times

At No. 107 Hospital of Jinan Military Command, deputy director Du Yingdong of the liver transplant center claimed, “Over 10 years ago, it took us over 10 hours to complete a liver transplant surgery. Now our technology has matured, and a liver transplant only takes 4 to 5 hours. Sometimes, 3 to 4 surgeries can be completed in one day. The speed of development has caught up to that of high-speed rail.”18 In April 2012, the hospital opened a new ward building, increasing its bed count from 600 to over 1,000.19

Shen Zhongyang, the director of Tianjin Oriental Organ Transplant Center, set a world record for the fastest liver transplant surgery in 2003, taking 2 hours and 4 minutes between making the incision and closing the abdomen. No blood transfusions were used during the operation. The previous record was 3 hours.20

Zhongshan Hospital of Shanghai Fudan University performed its first liver transplant in 1978. Since 2001, liver transplantation at this hospital has seen rapid development, with increased variety, more innovations, shorter operating times (4 to 6 hours on average), less bleeding, and fewer complications. Some patients are discharged 9 days after their operation. Transplant recipients include patients with liver cancer as well as other end-stage liver diseases. Its quantity and success rate of liver transplantation lead both the Shanghai region and the country.21

Zhongshan Hospital’s Liver Surgery Department recently started accelerating the transplant process time by performing surgery on patients immediately after their initial outpatient examination and hospital admission, This has attracted patients from more than 10 countries and regions, including the United States, the United Kingdom, Japan, Canada, South Korea, Hong Kong, Macau, and Taiwan.22 Even with a conservative two-week hospitalization stay, this hospital’s annual liver transplant volume can reach 5,000.


References

1
"Imported products are no longer the only dominant"
Original: http://www.gmw.cn/01gmrb/2004-08/01/content_68987.htm
Archived: http://archive.is/eKPLm
不再是进口产品“一枝独大”
2
"A novel immunosuppressant fingolimod: research advances"
Original: http://en.oversea.cnki.net/kcms/detail/detailall.aspx?filename=gwyz201301023&dbcode=CJFQ&dbname=CJFQ2013
Archived: http://archive.is/gSCly
新型免疫抑制剂芬戈莫德的研究进展
3
"Research progress of the application of immunosuppressants in organ transplantation"
Original: http://oa.paper.edu.cn/file.jsp?urltitle=%E5%85%8D%E7%96%AB%E6%8A%91%E5%88%B6%E5%89%82%E5%9C%A8%E5%99%A8%E5%AE%98%E7%A7%BB%E6%A4%8D%E4%B8%AD%E5%BA%94%E7%94%A8%E7%9A%84%E7%A0%94%E7%A9%B6%E8%BF%9B%E5%B1%95
免疫抑制剂在器官移植中应用的研究进展
4
"Research progress of immunosuppressant withdrawing after liver transplantation"
Original: http://www.organtranspl.com/expressnews/detail/qkid/67/id/251.html
Archived: http://archive.is/XYXaY
肝移植术后免疫抑制剂撤退的研究进展
5
"Key Laboratory of Organ Transplantation at Zhongshan Hospital of Shanghai Fudan University"
Original: http://yxky.fudan.edu.cn/6299/list.htm
Archived: https://archive.is/qZDmX
复旦大学附属中山医院器官移植重点实验室
6
"Imported products are no longer the only dominant"
Original: http://www.gmw.cn/01gmrb/2004-08/01/content_68987.htm
Archived: http://archive.is/eKPLm
不再是进口产品“一枝独大”
7
"Imported products are no longer the only dominant"
Original: http://www.gmw.cn/01gmrb/2004-08/01/content_68987.htm
Archived: http://archive.is/eKPLm
不再是进口产品“一枝独大”
8
"Special report on diagnosis and treatment of liver transplantation: Interview with West China Hospital liver transplant expert Yan Lvnan"
Original: http://paper.people.com.cn/jksb/html/2006-06/19/content_7050098.htm
Archived: http://archive.is/RaPvb肝移植诊治专题:采访华西医院肝移植专家严律南
9
"Organ transplant stimulating immunosuppressant market Source: Medical Economic News"
Original: http://business.sohu.com/20060328/n242513501.shtml
Archived: http://archive.is/vbSEi
器官移植催热免疫抑制剂市场 医药经济报
10
"China Science and Technology Development Report: Development of organ transplant immunosuppressant products"
Original: http://www.most.gov.cn/kjfz/kjxz/2011/201303/P020130314581869370712.pdf
中国科学技术发展报告:研制器官移植免疫抑制剂产品
11
"Investment prospects in the immunosuppressant industry"
Original: http://www.sentao.com.cn/upload/pdf/86.pdf
Archived: https://archive.is/i0d0h
免疫抑制剂行业的投资前景
12
"Immunosuppressant tacrolimus keeps a strong market, the domestic drug gradually rise up"
Original: https://read01.com/0eEd0M.html
Archived: https://archive.is/pH81f
免疫抑制剂他克莫司市场坚挺,国产药渐发力
13
"Immunosuppressant Market Growth Accelerates Novartis might be the Largest Winners China Pharmaceutical News September 20, 2010"
Original: http://www.bioon.com/industry/market/456985.shtml
Archived: https://web.archive.org/web/20170407074113/http://www.bioon.com/industry/market/456985.shtml
免疫抑制剂市场增长加速 诺华或成最大赢家 中国医药报 2010-9-20
14
"Winner of the Ninth Chinese Physician Prize – Tan Jianming"
Original: http://www.cmda.net/9ysjiang/detail/-id=76.htm
Archived: https://web.archive.org/web/20170109191334/http://www.cmda.net/9ysjiang/detail/-id=76.htm
第九届中国医师奖获奖医师谭建明
15
"Winner of the Ninth Chinese Physician Prize – Tan Jianming"
Original: http://www.cmda.net/9ysjiang/detail/-id=76.htm
Archived: https://web.archive.org/web/20170109191334/http://www.cmda.net/9ysjiang/detail/-id=76.htm
第九届中国医师奖获奖医师谭建明
16
"Introduction of Kidney Transplantation Department of Shanghai Changzheng Hospital"
Original: http://zyouh.u.yynet.cn/intro.php
Archived: https://archive.is/ol67I
上海长征医院肾移植科:主任医师朱有华
17
"Introduction of Shanghai Changzheng Hospital-Department of Organ Transplantation"
Original: http://www.shczyy.com/front/officeShow.aspx?id=21
Archived: https://web.archive.org/web/20160507170618/http://shczyy.com/front/officeShow.aspx?id=21
上海长征医院 器官移植科
18
"Giving Patients New Lives–Du Yingdong, Deputy Director of Department of Hepatobiliary Surgery at No. 107 Hospital Source: Jiaodong.net March 28, 2015"
Original: http://health.jiaodong.net/system/2015/03/27/012643942.shtml
Archived: https://web.archive.org/web/20160116210548/http://health.jiaodong.net/system/2015/03/27/012643942.shtml
生命在这重新崛起-107医院肝胆外科副主任杜英东 来源: 胶东在线 March 28, 2015
19
"The new hospital ward building was put into use in No. 107 Hospital Souhu.net/ Qilu Evening News Apr 22, 2012"
Original: http://m.sohu.com/n/341320996/?v=3
Archived: https://web.archive.org/web/20160212213443/http://m.sohu.com/n/341320996/?v=3
107医院新病房大楼启用 来源:搜狐网 / 齐鲁晚报 2012年4月22日
20
"“Tianjin First Central Hospital Sets Record, Uses 2 Hours to Complete a Liver Transplant Surgery” Source: Sohu, December 26, 2003."
Original: http://news.sohu.com/2003/12/26/97/news217489734.shtml
Archived: https://archive.is/rhpvK
天津一中心医院创纪录 仅用2小时完成肝移植手术 来源:新华网 2003年12月26日
21
"Introduction to Fudan University Organ Transplant Center"
Original: http://www.transplantation.com.cn/About.Asp
Archived: https://web.archive.org/web/20140726202428/http://www.transplantation.com.cn/About.Asp
复旦大学器官移植中心简介
22
"Introduction to Liver Surgery Department of Zhongshan Hospital of Fudan University"
Original: http://www.zs-hospital.sh.cn/keshi/detail.aspx?id=100001093&cid=150&kid=218
Archived: https://archive.is/dQlu1
复旦大学附属中山医院肝外科简介